Perspective Therapeutics (CATX) Other financing activities (2012 - 2023)

Perspective Therapeutics recorded quarterly Other financing activities of $65000.0 in Q1 2023, up 1146.17% quarter-over-quarter from $5216.0 in Q1 2012.

Perspective Therapeutics' Other financing activities history runs 2 years deep, the most recent figure standing at $65000.0 for Q1 2023.

  • In Q1 2023, Other financing activities changed N/A year-over-year to $65000.0; the TTM figure through Dec 2023 stood at $65000.0 (up 1146.17% YoY), while the FY2023 annual figure was $65000.0, changed N/A from the prior year.
  • Other financing activities came in at $65000.0 for Q1 2023 at Perspective Therapeutics, up from $5216.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $65000.0 in Q1 2023 to a low of $65000.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Perspective Therapeutics 380.23 Mn 380.23 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 65,000.00
Mar 31, 2023 65,000.00
Mar 31, 2012 5,216.00
Mar 31, 2012 5,216.00